Krystal Biotech, Inc. (KRYS) NASDAQ
293.21
-4.89(-1.64%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Krystal Biotech, Inc.
Address
2100 Wharton Street
Pittsburgh, PA 15203
United States of America (the)
Phone
412 586 5830
Website
Sector
Healthcare
Industry
Biotechnology
Employees
275
First IPO Date
September 20, 2017
Key Executives
| Name | Title | Pay | Year Born |
| Krish S. Krishnan | Founder, Chairman, President & Chief Executive Officer | 1.66M | 1965 |
| Kathryn A. Romano | Executive Vice President & Chief Accounting Officer | 674,756 | 1982 |
| Suma Krishnan | Founder, President of R&D and Director | 1.11M | 1965 |
| David Chien | Senior Vice President of Clinical Development | 0 | N/A |
| Stephane Paquette | Senior Vice President of Corporate Development | 0 | N/A |
| David Sweet | Director of Clinical Development | 0 | N/A |
| John Thomas | EVP, General Counsel & Corporate Secretary | 0 | 1974 |
| John Karakkal | Vice President of North American Sales & Marketing | 0 | N/A |
| Josh Suskin | Senior Director & Head of US Human Resources | 0 | N/A |
| Laurent Goux | Executive VP & Head of International | 0 | 1975 |
| Trevor Parry | Senior Vice President of Product Development | 0 | N/A |
| Christine Wilson | Senior VP & Head of US Commercial | 0 | N/A |
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
